19,668 Shares in Oric Pharmaceuticals, Inc. $ORIC Purchased by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC acquired a new position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 19,668 shares of the company’s stock, valued at approximately $200,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Arizona State Retirement System acquired a new stake in shares of Oric Pharmaceuticals in the first quarter worth approximately $56,000. New York State Common Retirement Fund boosted its stake in Oric Pharmaceuticals by 137.1% during the 1st quarter. New York State Common Retirement Fund now owns 38,486 shares of the company’s stock worth $215,000 after purchasing an additional 22,257 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Oric Pharmaceuticals by 54.1% during the 1st quarter. Victory Capital Management Inc. now owns 150,260 shares of the company’s stock worth $838,000 after purchasing an additional 52,760 shares during the last quarter. Legato Capital Management LLC purchased a new stake in shares of Oric Pharmaceuticals during the first quarter worth $109,000. Finally, TD Asset Management Inc raised its position in shares of Oric Pharmaceuticals by 3.3% in the first quarter. TD Asset Management Inc now owns 152,700 shares of the company’s stock valued at $852,000 after buying an additional 4,900 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Insider Activity

In related news, CEO Jacob Chacko sold 125,000 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $10.80, for a total transaction of $1,350,000.00. Following the completion of the transaction, the chief executive officer owned 656,419 shares of the company’s stock, valued at approximately $7,089,325.20. This trade represents a 16.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Dominic Piscitelli sold 11,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $14.52, for a total transaction of $159,720.00. Following the completion of the sale, the chief financial officer owned 48,317 shares of the company’s stock, valued at $701,562.84. This trade represents a 18.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 261,000 shares of company stock valued at $3,024,703. 5.55% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ORIC shares. Zacks Research upgraded shares of Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday, August 12th. JPMorgan Chase & Co. boosted their target price on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday. HC Wainwright upped their price target on Oric Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Friday. Citigroup increased their price target on Oric Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Finally, Wells Fargo & Company lowered their price objective on Oric Pharmaceuticals from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, November 14th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Oric Pharmaceuticals Stock Down 1.3%

ORIC stock opened at $11.90 on Wednesday. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.93. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -6.88 and a beta of 1.66. The business has a fifty day moving average of $12.25 and a two-hundred day moving average of $10.27.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. As a group, sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.